William J Kowalczyk1,2, Landhing M Moran1, Jeremiah W Bertz1, Karran A Phillips1, Udi E Ghitza3, Massoud Vahabzadeh4, Jia-Ling Lin4, David H Epstein1, Kenzie L Preston1. 1. a National Institute on Drug Abuse, Intramural Research Program , Clinical Pharmacology and Therapeutics Research Branch , Baltimore , MD, USA. 2. b Department of Psychology , Hartwick College , Oneonta , NY , USA. 3. c National Institute on Drug Abuse, Center for Clinical Trials Network , Bethesda , MD , USA. 4. d National Institute on Drug Abuse, Intramural Research Program , Biomedical Informatics Section , Baltimore , MD , USA.
Abstract
BACKGROUND: In a recent clinical trial (NCT00295308), we demonstrated that clonidine decreased the association between opioid craving and moderate levels of stress and affect in patients receiving buprenorphine-based opioid agonist therapy. OBJECTIVES: To examine the relationship between illicit opioid use and craving and affect during the evaluation of clonidine as an adjunct medication in buprenorphine treatment for opioid use disorder. Secondarily, to examine whether those relationships are driven by within- or between-participant factors. METHODS: This was a secondary data analysis from our original trial. Participants (N = 108, female: n = 23, male n = 85) receivingbuprenorphine were randomized to receive adjunct clonidine or placebo. Participants used portable electronic devices to rate stress, mood, and craving via ecological momentary assessment (EMA) four times randomly each day. To associate the EMA data with illicit opioid use, each EMA report was linked to participants' next urine drug screen (thrice weekly). We used generalized linear mixed models to examine the interaction between treatment group and illicit opioid use, as well as to decompose the analysis into within- and between-participant effects. RESULTS:Craving for opioids and cocaine was increased when participants were using illicit opioids; this effect was greater in the clonidine group. For affect, mood was poorer during periods preceding opioid-positive urines than opioid-negative urines for clonidine-treated participants, whereas there was no difference for placebo participants. CONCLUSION: This secondary analysis provides evidence that for participants maintained on opioid agonist therapy, clonidine minimized the behavioral impact of moderate levels of negative affect and craving.
RCT Entities:
BACKGROUND: In a recent clinical trial (NCT00295308), we demonstrated that clonidine decreased the association between opioid craving and moderate levels of stress and affect in patients receiving buprenorphine-based opioid agonist therapy. OBJECTIVES: To examine the relationship between illicit opioid use and craving and affect during the evaluation of clonidine as an adjunct medication in buprenorphine treatment for opioid use disorder. Secondarily, to examine whether those relationships are driven by within- or between-participant factors. METHODS: This was a secondary data analysis from our original trial. Participants (N = 108, female: n = 23, male n = 85) receiving buprenorphine were randomized to receive adjunct clonidine or placebo. Participants used portable electronic devices to rate stress, mood, and craving via ecological momentary assessment (EMA) four times randomly each day. To associate the EMA data with illicit opioid use, each EMA report was linked to participants' next urine drug screen (thrice weekly). We used generalized linear mixed models to examine the interaction between treatment group and illicit opioid use, as well as to decompose the analysis into within- and between-participant effects. RESULTS: Craving for opioids and cocaine was increased when participants were using illicit opioids; this effect was greater in the clonidine group. For affect, mood was poorer during periods preceding opioid-positive urines than opioid-negative urines for clonidine-treated participants, whereas there was no difference for placebo participants. CONCLUSION: This secondary analysis provides evidence that for participants maintained on opioid agonist therapy, clonidine minimized the behavioral impact of moderate levels of negative affect and craving.
Authors: Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson Journal: J Subst Abuse Treat Date: 2010-07-03
Authors: Helen C Fox; Dongju Seo; Keri Tuit; Julie Hansen; Anne Kimmerling; Peter T Morgan; Rajita Sinha Journal: J Psychopharmacol Date: 2012-01-09 Impact factor: 4.153
Authors: Henry R Kranzler; Stephen Armeli; Reagan Wetherill; Richard Feinn; Howard Tennen; Joel Gelernter; Jonathan Covault; Timothy Pond Journal: Addict Biol Date: 2014-12-15 Impact factor: 4.280
Authors: Leigh V Panlilio; Samuel W Stull; William J Kowalczyk; Karran A Phillips; Jennifer R Schroeder; Jeremiah W Bertz; Massoud Vahabzadeh; Jia-Ling Lin; Mustapha Mezghanni; Edward V Nunes; David H Epstein; Kenzie L Preston Journal: Drug Alcohol Depend Date: 2019-07-16 Impact factor: 4.492
Authors: Jennifer D Ellis; Chung Jung Mun; David H Epstein; Karran A Phillips; Patrick H Finan; Kenzie L Preston Journal: Neuropsychopharmacology Date: 2022-06-06 Impact factor: 8.294
Authors: Emmanuel E Alvarez; Sahar Hafezi; Darla Bonagura; Evan M Kleiman; Anna B Konova Journal: Front Psychiatry Date: 2022-05-17 Impact factor: 5.435
Authors: Jeremiah W Bertz; David H Epstein; David Reamer; William J Kowalczyk; Karran A Phillips; Ashley P Kennedy; Michelle L Jobes; Greg Ward; Barbara A Plitnick; Mariana G Figueiro; Mark S Rea; Kenzie L Preston Journal: J Subst Abuse Treat Date: 2019-08-14
Authors: Garrett James Jenkins; Michael J Cleveland; Kyler Scott Knapp; Scott C Bunce; H Harrington Cleveland Journal: Addict Behav Date: 2020-09-24 Impact factor: 3.913